A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.
Tanya Barauskas DorffLisa G HorvathKaren A AutioAlice Bernard-TessierMatthew B RettigJean-Pascal H MachielsMehmet Asim BilenMartijn Paul LolkemaNabil AdraSylvie RotteyRichard GreilNobuaki MatsubaraDaniel Shao-Weng TanAlvin S C WongHiroji UemuraCharlotte LemechJohannes MeranYoufei YuMukul MinochaMason McCombHweixian Leong PennyVinita GuptaXuguang HuGabor JuridaHosein Kouros-MehrMargit M Janát-AmsburyTobias EggertBen TranPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Acapatamab was safe and tolerated and had a manageable CRS profile. Preliminary signs of efficacy with limited durable antitumor activity were observed. Acapatamab demonstrated pharmacokinetic and pharmacodynamic activity.